Loading...
By Joe Elia
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
Drugs known as PCSK9 inhibitors, although effective at lowering LDL cholesterol, are too expensive to be cost-effective, a JAMA analysis finds.
Researchers used 2015 drug prices and national health data to construct models of cost effectiveness in two groups approved for using PCSK9 inhibitors: people with heterozygous familial hypercholesterolemia and those with atherosclerotic cardiovascular disease. PCSK9 inhibitors cost roughly $15,000 per year wholesale.
Compared with adding ezetimibe to statin therapy over the patients' lifetimes, adding PCSK9 inhibition in familial hypercholesterolemia would prevent over 300,000 additional cardiovascular deaths, nonfatal heart attacks, and strokes — but at cost of over $500,000 per quality-adjusted life-year (QALY). Similarly, in atherosclerotic disease, over 4 million serious events would be averted, but would cost over $400,000 per QALY.
The authors point out that achieving a QALY of $100,000 would necessitate lowering PCSK9 costs by about two thirds — to about $4500 annually.
Comment
LINK(S):
JAMA article (Free)
Background: Physician's First Watch coverage of cost of PCSK9 inhibitors (Free)